Clear Search sequence regions
Bookmark Forward

QuickView for Prazosin (compound)


PubChem
Name: Prazosin
PubChem Compound ID: 450782
Description: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
Molecular formula: C19H21N5O4
Molecular weight: 382.402 g/mol
Synonyms:
MOLI001320
DrugBank
Identification
Name: Prazosin
Name (isomeric): DB00457
Drug Type: small molecule
Description: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
Synonyms:
Prazosin HCl; Prazosina [INN-Spanish]; Prazocin; Prazosin Hydrochloride; Prazosine [INN-French]; Prazosinum [INN-Latin]
Brand: Minipress Xl, Lentopres, Minipress, Furazosin, Vasoflex
Brand name mixture: Minizide(prazosin + polythiazide)
Category: Alpha-adrenergic Blocking Agents, Adrenergic alpha-Antagonists, Antihypertensive Agents
CAS number: 19216-56-9
Pharmacology
Indication: For treatment of hypertension, symptomatic benign prostatic hyperplasia, and severe congestive heart failure. May also be used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma.
Pharmacology:
Prazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Prazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Prazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity...
show more »
Mechanism of Action: Prazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
Absorption: Well-absorbed from gastrointestinal tract; bioavailability is variable (50 to 85%).
Protein binding: 97%
Biotransformation: Primarily hepatic. Several metabolites have been identified in humans and animals (6- O -demethyl, 7- O -demethyl, 2-[1-piperazinyl]-4-amino-6, 7-dimethoxyquinazoline, 2,4-diamino-6,7-dimethoxyquinazoline).
Route of elimination: Animal studies indicate that prazosin hydrochloride is extensively metabolized, primarily by demethylation and conjugation, and excreted mainly via bile and feces. Less extensive human studies suggest similar metabolism and excretion in man.
Half Life: 2-3 hours
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Avoid alcohol.
Take without regard to meals.
Avoid natural licorice.
Drug interaction:
AtenololRisk of hypotension at the beginning of therapy
VardenafilAdditive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Prazosin, may occur. Monitor for hypotension during concomitant therapy.
PindololRisk of hypotension at the beginning of therapy
Dabigatran etexilateP-Glycoprotein inducers such as prazosin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
MetoprololRisk of hypotension at the beginning of therapy
show more »

Targets


Enzymes


Transporters


Carriers